<DOC>
	<DOCNO>NCT02910219</DOCNO>
	<brief_summary>Chemotherapy induce diarrhea see 40-80 % patient receive treatment HER2 positive locally advanced metastatic breast cancer . This diarrhea significantly impact patient 's quality life ability tolerate chemo/anti-HER2 therapy . This study look efficacy drug crofelemer prevent diarrhea breast cancer patient .</brief_summary>
	<brief_title>Diarrhea Prevention Prophylaxis With Crofelemer HER2 Positive Breast Cancer Patients</brief_title>
	<detailed_description>Various anti-diarrheal agent , loperamide , codeine , octreotide , available diarrhea management , use prophylactic set none provide target approach treat chemotherapy induce diarrhea ( CID ) . Pre-clinical study suggest block EGFR result excess chloride secretion thus diarrhea . Crofelemer extract blood red bark Croton lechleri inhibits luminal chloride efflux block calcium activate chloride channel ( CaCC ) cystic fibrosis transmembrane regulator ( CFTR ) chloride channel . Due size polarity , act luminally systemically absorb . It currently FDA approve use prevent diarrhea HIV/AIDS patient anti-retroviral therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Willing able provide write informed consent ; 2 . Men woman ≥18 year age ; 3 . Pathologically confirm diagnosis HER2 positive breast cancer stage ( previous treatment allow without limit line prior therapy ) ; 4 . Scheduled receive least 3 consecutive cycle THP TCHP ; 5 . Performance status 02 accord ECOG scale ; 6 . Negative pregnancy test time inform consent woman childbearing potential ; 7 . Able read , understand , follow study procedure complete crofelemer , rescue medication , bowel movement diary ; 8 . Patients may enroll simultaneously study study , include limited NSABP B52 ; 9 . Patients brain metastasis ( include concurrent steroid treatment ) allow study . 10 . Left Ventricular Ejection Fraction ( LVEF ) great equal 50 % baseline determine either ECHO MUGA 1 . Pregnant and/or breastfeeding ; 2 . Ongoing irritable bowel syndrome ( IBS ) colitis ( include limit ulcerative colitis , Crohn 's disease , microscopic colitis , etc . ) ; 3 . Use investigational drug within 3 week sign consent foreseen use study ; 4 . Use chemotherapy , trastuzumab , pertuzumab within past 3 week ; 5 . Use laxatives within past 7 day ; 6 . Use chronic laxative ( ≥ 30 consecutive day ) ; 7 . Use antidiarrheal agent ( include limit loperamide , octreotide , bismuth , tincture opium , atropine , probiotic form food ) within past 7 day ; 8 . Use antibiotic within past 7 day ; 9 . Any type ostomy ; 10 . Total colectomy ; 11 . Fecal incontinence ; 12 . Ongoing radiation induce diarrhea constipation plan radiotherapy abdomen pelvis study ; 13 . Active systemic infection require ongoing intervention , include limited oral intravenous antibiotic , antifungal , antiparasites , antiviral ; 14 . Major abdominal pelvic surgery within past 6 month ; 15 . Inadequate organ function start THP TCHP , may include follow laboratory result within 28 day prior sign consent : 1 . Total bilirubin &gt; upper limit normal ( ULN ) ( unless patient document Gilbert 's syndrome ) 2 . Serum creatinine &gt; 2.0 mg/dL 177 μmol/L 3 . AST ( SGOT ) ALT ( SPGT ) &gt; 2.5 ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HER2</keyword>
	<keyword>pertuzumab</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>docetaxel</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>crofelemer</keyword>
	<keyword>chemotherapy induce diarrhea</keyword>
</DOC>